Lukas Biomedical Inc.
Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. The company operates through E-Commerce Department, Medical Management Business, Cell Products Department, and Pharmaceutical Market Development Department segments. It also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distribute… Read more
Lukas Biomedical Inc. - Asset Resilience Ratio
Lukas Biomedical Inc. (6814) has an Asset Resilience Ratio of 0.05% as of June 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2019)
This chart shows how Lukas Biomedical Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Lukas Biomedical Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$249.00K | 0.05% |
| Total Liquid Assets | NT$249.00K | 0.05% |
Asset Resilience Insights
- Limited Liquidity: Lukas Biomedical Inc. maintains only 0.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lukas Biomedical Inc. Industry Peers by Asset Resilience Ratio
Compare Lukas Biomedical Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Lukas Biomedical Inc. (2019–2019)
The table below shows the annual Asset Resilience Ratio data for Lukas Biomedical Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 0.09% | NT$498.00K | NT$556.12 Million | -- |